The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More
News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW. This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer. The… Read More
Aston University has been awarded €1.2 million to fund an international project developing cancer tumour-fighting ‘magnetobots’. The university was awarded the funding through the Marie Skłodowska-Curie Actions (MSCA) Staff Exchanges programme for the project bringing together 18 partner organisations. The magnetobots, made from microorganisms called magnetotactic bacteria, will combine theranostic technologies to… Read More
Cancer patients are being denied access to a “game changer” method of treatment, a new study warns. Health economists Dr Yufan Wang and Professor Haitham Tuffaha led a review into the value of theranostic nuclear medicine, an innovative frontier in cancer treatment, and concluded patients are being… Read More
Denis R Beckford-Vera, Head of Radiopharmacology at Champions Oncology explores how radiopharmaceuticals can benefit from the use of patient-derived xenograft models. The rising promise of radiopharmaceuticals Targeted radionuclide therapies (TRTs) are rapidly becoming a major force in oncology drug development. These agents combine a tumour-targeting molecule with a radioactive… Read More
Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has dosed the first patient with its first-in-class lead molecule, satoreotide, targeting extensive stage small cell lung cancer (ES-SCLC), at the Murdoch University Health Center in Perth, Australia. Ariceum has… Read More
By Dr Mikael Kubista Quantitative real-time PCR is becoming mature technology for the quantification of nucleic acids. It is spreading wide outside its original use in the research laboratories, becoming preferred technology for a range of applications, many that require specialised so lutions and adaptations. Integration with pre-analytical steps and… Read More
By Dr Stephen Naylor and Toby Cole In this article we describe the current state of Companion Diagnostics and its impact on the pharmaceutical sector, and the need for Companion Diagnostics in the drug discovery and development process. This perspective is augmented… Read More
Industry Strategies on Theranostics: Need for structural alignment Dr Rutger O. van Merkerk and Dr Wouter P.C. Boon Theranostics is said to change the way patients will manage their disease. Such a change assumes that diagnostics and therapeutics become increasingly linked based on genetic information. Companies that… Read More
Genetics & Personalised Medicine – Whole genome association and genetic linkage studies By Dr John W. Hooper Genetic linkage studies have long been the standard for researching the genetics associated with heritable diseases. Recently, however, scientists have begun to realise the benefits of whole genome association studies,… Read More
The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity By Dr Kenneth C. Carter Conventional drug discovery and development is centred on a paradigm in which ‘validated’ targets are subjected to in vitro screens for the identification of new drug candidates. Read More
Fewer drugs approved, more money spent – Where’s the beef? By G. Steven Burrill Three years ago, when biotech was at its Wall Street heights, personalised medicine and its promise were on everyone’s lips. Billions of dollars were being put to work to make targeted medicine a… Read More
By Dr Ian Gilham The increasing cost of healthcare along with new opportunities for improved treatments puts ever increasing pressures on healthcare budgets. In recent years the diagnostic industry in particular has been the target of a number of cost-cutting exercises by governments and payers aimed… Read More
